Ceres Inc (CERE) News
Filter CERE News Items
CERE News Results
|Loading, please wait...|
CERE News Highlights
- For CERE, its 30 day story count is now at 4.
- Over the past 1 day, the trend for CERE's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
- MG, CORT and MITO are the most mentioned tickers in articles about CERE.
Latest CERE News From Around the Web
Below are the latest news stories about Cerevel Therapeutics Holdings Inc that investors may wish to consider to help them evaluate CERE as an investment opportunity.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Stealth Biotherapeutics (MITO – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with bullish sentiments. Corcept Therapeutics (CORT) H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics today and set a price target of $29.00. The company's shares closed last Tuesday at $20.31. According to TipRanks.
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter 2021 financial results and recent business updates on Tuesday, March 1, 2022 at 8:00 a.m. ET. To access the call, ple
Cerevel Therapeutics Holdings Inc's (NASDAQ: CERE) 7.5 mg twice daily and the 25 mg twice-daily doses of darigabat demonstrated clinically meaningful and statistically significant anxiolytic activity in healthy volunteers compared with placebo. After eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses demonstrated a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the primary endpoint of the Panic Symptoms List (PSL-IV) total score. The positive contro
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo Darigabat was generally well-tolerated; resulted in no serious adverse events and no treatment-related discontinuations in the trialCerevel intends to advance development of darigabat in anxiety-related disordersConference call and webcast scheduled for today
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for emraclidine in schizophrenia by the middle of 2022, with data expected in the first half of 2024 Phase 1 trial for darigabat in acute anxiety completed; data is expected in the next several weeks Phase 2a data for CVL-871 in dementia-related apathy now expected 1H 2023; delayed from 2H 2022, due in
Investment company Tarbox Family Office, Inc. (Current Portfolio) buys iShares Core Total USD Bond Market ETF, iShares Core MSCI Total International Stock ETF, BTC iShares International Aggregate Bond Fund, IGM Biosciences Inc, Fisker Inc, sells Alphabet Inc, AT&T Inc, Meta Platforms Inc, Trex Co Inc, JPMorgan Chase during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Tarbox Family Office, Inc..
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by Chief Medical Officer Raymond Sanchez, M.D., and Chief Scientific Officer John Renger, Ph.D., for the question-and-answe
One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year
Viewing insider transactions for Cerevel Therapeutics Holdings, Inc.'s ( NASDAQ:CERE ) over the last year, we see that...
These cryptos to buy for multi-fold returns in the next few quarters are flying under the radar but have a strong utility.
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia
Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptoms of schizophreniaCAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to